As a genre, the “award acceptance lecture” is little more than a formality and a banality. But there is at least one charming exception to this rule—the talks given by the foremost computer scientists ...
Researchers have built a pull request that steals a repository's secrets by hiding the malicious instruction inside a PNG that AI code reviewers never open. The reviewer waves the change through.
Trump's policy that narrowed eligibility for Public Service Loan Forgiveness will not go into effect, after two federal judges blocked the rule. PSLF, signed into law in 2007 by George W. Bush, offers ...
PITTSFIELD – When the state’s affordable housing finance agency launched a multimillion-dollar grant program to fix up blighted properties in struggling mill towns three years ago, the biggest chunk ...
The South Florida Water Management District's Python Elimination Program rewards hunters for removing the invasive snakes. In May 2026, contracted hunters eliminated 315 python eggs from the ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
Deckers' fiscal 2026 fourth-quarter sales grew 10% on increases of 15% and 9% for Hoka (60% of sales) and Ugg (37%), respectively. Its gross margin rose 90 basis points (to 57.6%) despite negative ...
WASHINGTON — Rocket Lab said May 7 it won new Pentagon-related defense business tied to the Trump administration’s Golden Dome missile defense initiative and to the expanding U.S. push to accelerate ...
A new study led by researchers from VIB and KU Leuven shows that Parkinson's disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using ...
CHARLOTTE, N.C.--(BUSINESS WIRE)--RXO (NYSE: RXO) a leading provider of asset-light transportation solutions, today announced it has expanded its RXO Extra™ marketplace, where carriers can access ...
Preparations underway to advance AP-101 into confirmatory Phase 3 clinical trial with initiation aimed for late 2026 ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company ...
ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis ...